SCHEMBL20249240

SCHEMBL20249240

CC(C)(C)c1ccc(N2CC3(CCCN3)C2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.46
CHRNA4 P43681 3/20 0.46
CHRNB4 P30926 2/20 0.46
CHRNA3 P32297 2/20 0.46
CHRNA1 P02708 1/20 0.46
CHRNG P07510 1/20 0.46
CHRNB1 P11230 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRND Q07001 1/20 0.46
JAK3 P52333 1/20 0.37
ROCK1 Q13464 11/20 0.34
CDC42BPB Q9Y5S2 11/20 0.34
ROCK2 O75116 4/20 0.34
CDC42BPA Q5VT25 4/20 0.34
OPRL1 P41146 1/20 0.34
USP25 Q9UHP3 1/20 0.34
RET P07949 1/20 0.33
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
PIM2 Q9P1W9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249245 0.93 CHRNB2 (0.51) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1
SCHEMBL18291579 0.82 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1
SCHEMBL20249246 0.79 ALDH1A1 (0.45) CHRNB2CHRNA4ROCK1CDC42BPBROCK2
SCHEMBL20249239 0.79 CYP3A4 (0.33) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL20038119 0.78 CHRNB2 (0.48) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1
SCHEMBL20249244 0.78 TSHR (0.50) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL20255190 0.76 CHRNB2 (0.34) CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1
SCHEMBL20249248 0.76 TSHR (0.41) CHRNB2CHRNA4CHRNB4CHRNA3PIM1
SCHEMBL20249323 0.75 CDK4 (0.42) OPRL1
SCHEMBL20249243 0.74 CDK4 (0.40) CHRNB2CHRNA4CHRNB4CHRNA3PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 CHRNB2 4863/4885CHRNA4 4628/4885CHRNB4 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.